表紙
市場調查報告書

化膿性汗腺炎 (HS)的流行病學的預測

Hidradenitis Suppurativa (HS): Epidemiology Forecast to 2028

出版商 GlobalData 商品編碼 907773
出版日期 內容資訊 英文 26 Pages
訂單完成後即時交付
價格
化膿性汗腺炎 (HS)的流行病學的預測 Hidradenitis Suppurativa (HS): Epidemiology Forecast to 2028
出版日期: 2019年07月31日內容資訊: 英文 26 Pages
簡介

本報告提供全球主要7個國家 (美國、德國、法國、義大利、西班牙、英國、日本) 的化膿性汗腺炎 (HS)的發病情形與今後預測相關分析,疾病的特徵,及目前患病者的發病情形,今後10年的患病數量的預測值等調查評估。

第1章 目錄

第2章 化膿性汗腺炎 (HS):摘要整理

第3章 流行病學

  • 疾病的背景情況
  • 風險要素和共生病症
  • (EU5過去的流行病學的趨勢:全球,各地區 (美國,歐洲主要5個國家))
  • 預測手法
    • 資訊來源
    • 前提條件與預測手法
  • 化膿性汗腺炎 (HS)的流行病學的預測
    • 確診的患病人數
    • 確診的患病人數:各年齡
    • 確診的患病人數:男女
    • 確診的患病人數:各重症度
    • 確診的患病人數:男女
    • 確診的患病人數:併發了發炎性腸道疾病 (IBD) 的情況
  • 討論
    • 流行病學的預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

目錄
Product Code: GDHCER208-19

Diagnosed prevalent cases of Hidradenitis Suppurativa (HS) are expected to increase at an Annual Growth Rate (AGR) of 0.11% from 780,000 cases in 2018 to 800,000 cases in 2028 in the seven major markets (US, France, Germany, Italy, Spain, UK, and Japan).

Hidradenitis Suppurativa (HS) is a long term, recurrent skin condition that causes painful lumps under the skin that form near the hair follicles where there are sweat glands. HS is characterized by abscesses and scarring on the skin. The abscesses may break open and leak pus or cause tunnels under the skin. The cause of HS is not known, but is thought to have a link to a genetic link because a third of all cases have a relative with HS.

HS is not a life-threatening condition, but does have a major impact on the patients' quality of life. Some patients develop depression due to the social isolation, pain, and embarrassment they experience associated with the symptoms of HS. The cause of HS is not well understood, future epidemiologic research that investigates the cause and prevalence of HS is important to gain further insight into the frequency of disease, risk factors associated with it, and treatment.

The report "Hidradenitis Suppurativa (HS): Epidemiology Forecast to 2028", found that there is insufficient chronological data to assess changes in the prevalence of HS over time, therefore, the most recent estimate of diagnosed prevalence of HS was held constant for the forecast period for all the markets. The report also found that the US had the highest number of diagnosed prevalent cases of HS. In Germany and Japan, however, diagnosed prevalent cases of HS is expected to decline during the forecast period while all other markets are expected to see an increase.

Scope:

  • The Hidradenitis Suppurativa (HS) Epidemiology Report provides an overview of the risk factors and global trends of HS in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • This report also includes a 10-year epidemiological forecast for the following segmentations in ages 18 years and older across the 7MM: diagnosed prevalent cases of HS; diagnosed prevalent cases of HS by severity; diagnosed prevalent cases of HS with inflammatory bowel disease.
  • The HS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy:

The Hidradenitis Suppurativa Epidemiology report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global HS market.
  • Quantify patient populations in the global HS market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for HS therapeutics in each of the markets covered.
  • Understand magnitude of HS population by severity.
  • Quantify the population of HS population with IBD.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Hidradenitis Suppurativa: Executive Summary

  • 2.1. Related Reports
  • 2.2. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global and Historical Trends
    • 3.3.1. US
    • 3.3.2. 5EU
  • 3.4. Forecast Methodology
    • 3.4.1. Sources
    • 3.4.2. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for HS (2018-2028)
    • 3.5.1. Diagnosed Active Prevalent Cases of HS
    • 3.5.2. Age-Specific Diagnosed Active Prevalent Cases of HS
    • 3.5.3. Sex-Specific Diagnosed Active Prevalent Cases of HS
    • 3.5.4. Diagnosed Active Prevalent Case of HS by Severity
    • 3.5.5. Diagnosed Active Prevalent Cases of HS with IBD
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. Primary Research - Prescriber Survey
  • 4.3. About the Authors
    • 4.3.1. Epidemiologist
    • 4.3.2. Reviewers
    • 4.3.3. Global Director of Therapy Analysis and Epidemiology
    • 4.3.4. Global Head and EVP of Healthcare Operations and Strategy
  • 4.4. About GlobalData
  • 4.5. Contact Us
  • 4.6. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for Hidradenitis Suppurativa
  • Table 2: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: 7MM, Diagnosed Active Prevalent Cases of HS, Both Sexes, Ages ≥18 Years, 2018 and 2028, N
  • Figure 2: Diagnosed Active Prevalence of HS, 7MM, Men and Women, Ages ≥18 Years, 2018, (%)
  • Figure 3: Sources Used and Not Used for Diag